Study of LV009 injection for CD19-positive blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called LV009 for people with certain blood cancers (like leukemia or lymphoma) that have come back or not responded to standard therapy. It aims to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be CD19-positive and considered relapsed or refractory (came back or didn't respond to treatment).
- You must be generally active (able to care for yourself or up and about more than half the day).
- Your heart, liver, and kidneys must be working well enough based on blood tests and scans.
- You cannot have serious active infections or other cancers (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This trial tests a new immune cell therapy (CAR-γδ T cells) that targets a protein called CD19 found on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments.
This trial tests an investigational cell therapy called B019 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The therapy targets cancer cells that have CD19 and/or CD22 on their surface, and the study aims to see if it is safe and effective.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Hear when a new CD19+ Relapse/Refractory B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.